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INTRODUCTION
Pilocytic astrocytomas are the second most common tumor seen in individuals with Neurofibromatosis Type 1 (NF1) with approximately 15% of children affected by NF1 exhibiting optic pathway gliomas [1] [2] [3] . As previously shown for other tumor pre-disposition syndromes, individuals with NF1 begin life with one mutated and one functional copy of the Nf1 gene. Nf1 encodes a novel tumor suppressor protein named neurofibromin that acts as a GTPase activating protein to functionally inactivate Ras molecules [4] [5] [6] [7] . While much has been learned about how neurofibromin inactivates Ras, only recently has effort been spent dissecting the numerous downstream signaling pathways affected by Nf1 loss. Specifically, little is known about the role of neurofibromin in regulating cell growth, increases in protein production, and how this might effectively manipulate astrocyte proliferation. A recent study demonstrated that nucleophosmin (NPM) was highly expressed in Nf1-deficient astrocytes along with numerous other ribosomal biosynthesis proteins 8 . NPM is a nucleolar proto-oncogene whose expression is tightly regulated by growth factor signals 9, 10 . Additionally, NPM mRNA contains a signature 5'-terminal oligo-pyrimidine tract that responds to S6K signals for its active translation, placing NPM downstream of the mTOR/S6K cascade 11 . Increasing efforts have been placed on identifying the biological role of NPM in promoting cell growth and proliferation. To this end, several groups have reported that NPM is the target of the nucleolar ARF tumor suppressor, underscoring the importance of NPM in promoting cell growth [12] [13] [14] . ARF inhibits both the ribosome processing and nuclear export functions of NPM to induce proliferative arrest, providing insights into the critical growth-promoting functions of NPM 12, 13 . Nuclear export of NPM requires a conserved Crm1 motif and, although we have not published these preliminary data, mutation of two leucine residues to alanines at positions 42 and 44 results in the nuclear retention of NPM. We propose to evaluate the role of aberrant S6K/NPM activities on Nf1-null astrocyte growth and proliferation.
The purpose of this study is demonstrate the impact of aberrant NPM expression on astrocytes lacking Nf1 in order to more completely understand the growth and proliferative advantages bestowed upon these cells. The specific aims of this project are to 1) determine whether loss of Nf1 results in NPM-directed increases in ribosome production and 2) examine the sensitivity of NPM-overexpressing Nf1-null astrocytes to S6K inhibition. Since NPM has been shown to be overexpressed in the absence of neurofibromin, we propose that increases in NPM will augment ribosome biogenesis. We have generated a dominant negative NPM mutant that suppresses nuclear export of the ribosome in wildtype mouse embryonic fibroblasts. Using this novel export inhibitor, we will determine whether NPM directs nuclear export of ribosomes in astrocytes. Additionally, we will determine the contribution of hyperactivated S6K to increases in NPM expression, ribosome export and growth in Nf1-deficient astrocytes. This could reveal a novel therapeutic pathway responsible for regulating Nf1-null cell growth and proliferation.
We have obtained Nf1-null astrocytes and have used these cells for in vitro manipulations involving retroviral infection, Nucleofector TM transduction, cell growth and proliferation assays, and Western and Northern blot analysis. We have frequently performed all of the assays outlined in the Statement of Work including ribosomal RNA export, labeling of newly synthesized ribosomal RNAs, S6K activity assays, BrdU incorporation into replicating DNA, flow cytometry for DNA analysis, and proliferation assays. We are in possession of the NPM export mutant as well as the dominant negative S6K construct. We believe that the insights gained from this study will greatly improve our understanding of the mechanism(s) by which neurofibromin loss promotes cell growth and proliferation. This work, although performed in primary astrocytes, could be translated into any number of cell systems implicated in NF1 due to its mechanistic and evolutionary conservation. In addition, our results will open up a new generation of targets aimed at disrupting aberrant protein translation networks that appear to go awry during Neurofibromatosis.
BODY
Neurofibromatosis type 1 (NF1) is a common autosomal dominant tumor predisposition syndrome in which affected individuals develop astrocytic brain tumors (gliomas). To determine how the NF1 gene product (neurofibromin) regulates astrocyte growth and motility relevant to glioma formation, we have employed Nf1-deficient primary murine astrocytes. Nf1-/-astrocytes exhibit increased protein translation and cell proliferation 8 , which are mediated by Ras-dependent hyperactivation of the mammalian target of rapamycin (mTOR) protein, a serine/threonine protein kinase that regulates ribosomal biogenesis, protein translation, actin cytoskeleton dynamics, and cell proliferation. In this study, we demonstrate that Nf1-deficient astrocytes have fewer actin stress fibers and exhibit increased cell motility compared to wild-type astrocytes, which are rescued by pharmacologic and genetic mTOR inhibition. We further show that mTOR-dependent regulation of actin stress fiber formation, motility, and proliferation requires rapamycinsensitive activation of the Rac1 GTPase, but not 4EBP1/S6K. Nf1-/-astrocytes also exhibit increased protein translation and ribosomal biogenesis through increased expression of the nucleophosmin (NPM) nuclear-cytoplasmic shuttling protein. We found that NPM expression in Nf1-/-astrocytes was blocked by rapamycin in vitro and in vivo, and that expression of a dominant-negative NPM mutant protein in Nf1-/-astrocytes rescued actin stress fiber formation and restored cell motility and proliferation to wild-type levels.
Together, these data demonstrate that neurofibromin regulates actin cytoskeleton dynamics and cell proliferation through an mTOR/Rac1-dependent signaling pathway and identify NPM as a critical mTOR effector mediating these biologic properties in Nf1-deficient astrocytes. This data will be discussed in detail below.
First, we demonstrate that primary astrocytes lacking Nf1 exhibit enhanced cytoplasmic polysomes, ribosomes actively translating mRNAs (Figure 1 ). This experiment was performed exactly as outlined in our Statement of Work, Task 1. Astrocytes from wildtype and Nf1-deficient mice were plated in equal numbers, lysed and separated over sucrose gradients. The gradient was then analyzed by constant UV monitoring to determine where the rRNA fractions separated. A trace of this analysis is shown in Figure  1 and allows us to accurately measure the relative amounts of cytosolic ribosomes for each setting.
Second, in order to answer the question proposed in the second part of Task 1, we determined that the increase in polysome formation in Nf1-deficient cells required functional NPM. Overexpression of Nf1-null astrocytes with a shuttling defective, dominant negative NPM mutant (NPMdL) resulted in a nearly complete inhibition of polysome content (Figure 2 ).
The final experiment outlined in Task 1 of our Statement of Work involved understanding the contribution of NPM function to the enhanced proliferation of Nf1-deficient astrocytes. In order to answer this extremely important question, we again transduced astrocytes with the NPMdL dominant negative mutant. Similar to the inhibition of polysome formation in Nf1-/-astrocytes transduced with NPMdL, expression of the NPMdL mutant also inhibited proliferation of Nf1-null astrocytes (Figure 3 ), suggesting that NPM nuclear export functions are absolutely required for enhanced Nf1-/-astrocyte proliferation. These results completed our analysis of ribosome content in cells lacking neurofibromin and also completed all of the experiments described in Task 1 of the Statement of Work. Nf1-/-astrocytes transduced with NPMdL mutant were unable to maintain increased numbers of polysomes.
For Task 2 of our Statement of Work, we had hypothesized that S6K1 acted downstream of mTOR to induce NPM expression and subsequent increases in polysome content in the absence of neurofibromin. However, our initial experiments provided evidence that S6K1 was not the upstream regulator of NPM. First, we determined that NPM expression in vivo was sensitive to rapamycin (Figure 4 ), indicating that mTOR is an upstream activator of NPM expression. Phospho-S6 and NPM are expressed at low levels in wild-type murine optic nerve (Nf1f/f), but are dramatically increased in a murine model of optic glioma (Nf1f/mut;GFAP-Cre), as shown by immunohistochemistry. Following rapamycin treatment in vivo, both NPM and P-S6 expression are decreased in the mouse optic gliomas. Scale bar=200 μm (10X). NPM function was inhibited genetically using a mutant protein (NPMdL) that can not shuttle between the nucleus and cytoplasm. Inhibition of NPM shuttling activity in Nf1-/-astrocytes restored cell proliferation to wild-type levels. Inhibition of NPM shuttling function had no effect on proliferation in wildtype cells. *, p< 0.05 Second, using a retroviral transduction system, we set out to determine the contribution of S6K1 to NPM expression in astrocytes. We reasoned that by overexpressing activated S6K1 in wild-type astrocytes, we should be able to push NPM expression to levels seen in Nf1-deficient astrocytes. This would show that S6K1 was the critical upstream regulator of NPM expression in astrocytes and could provide a novel target for inhibition in Nf1-deficient astrocytes. However, overexpression of S6K1 in wild-type astrocytes did not result in an increase in NPM protein expression ( Figure 5A ) even though it was still capable of phosphorylating S6. Even though this answered one of our major questions for Task 2, we could not move forward in our analysis of S6K1 as previously proposed, because it simply had no effect on NPM expression in astrocytes. This is strike contrast to its ability to regulate NPM expression in fibroblasts 14 . So we took a new approach to completing experiments for Task 2. Rac1 is a common target of the mTORC2 complex and we had generated preliminary data with Dr. David Gutmann suggesting that actin cytoskeletal changes (see attached paper) were regulated by loss of Nf1 and increased NPM expression. Many of these changes can be attributed to Rac1 given its ability to regulate the actin cytoskeleton. We also hypothesized that Rac1 might also regulate NPM expression in cells lacking Nf1. Indeed, Nf1-/-astrocytes transduced with a dominant negative Rac1 mutant (Rac1 N17 ) displayed severe attenuation in NPM protein expression ( Figure 5B ), suggesting that Rac1 is responsible for regulating NPM expression in cells lacking Nf1.
Additional data and findings can be found in the appendices. Overall our findings point to NPM as a novel mediator of pro-growth, -proliferation, -motility, and -cytoskeleton changes in astrocytes lacking Nf1. These findings should provide a unique target in NPM for future studies into the therapeutic potential of targeting NPM function in Neurofibromatosis. 
KEY RESEARCH ACCOMPLISHMENTS

CONCLUSIONS
This proposal was designed to determine the role of NPM in the proliferation of Nf1-/-astrocytes. To this end, we now provide evidence that NPM protein expression is elevated in Nf1-/-cells and that this up-regulation is completely abrogated by rapamycin treatment. Interestingly, induction of NPM through Nf1 loss was not regulated by S6K but rather by Rac signal transduction. This is in contrast to NPM pathway regulation in fibroblasts where NPM protein induction is completely dependent on S6K activities 14 . Additionally, we now know that NPM regulates cytoskeletal changes in Nf1-deficient astrocytes. While we are not yet certain as to whether these effects are directly regulated by NPM proteins, we have now shown that nucleocytoplasmic shuttling of NPM is required for all of the biological effects of NPM (growth, proliferation and cytoskeletal changes) on Nf1-/-astrocytes. Taken together, our data now provides a compelling foundation for the further analysis of NPM as a potentially new therapeutic target in Neurofibromatosis. To study the role of neurofibromin in astrocyte growth regulation and glioma formation, our laboratory has developed several murine models of NF1-associated neurologic disease by conditionally inactivating Nf1 expression in brain astrocytes (7) (8) (9) . Studies of these geneticallyengineered mouse models and derivative astrocytes have revealed that Nf1-/-astrocytes have several unique biologic properties. First, Nf1-/-astrocytes exhibit increased cell proliferation both in vitro and in vivo (8, 10) . This increase in astrocyte proliferation requires Ras-dependent hyperactivation of the mammalian target of rapamycin (mTOR), a serine/threonine protein kinase that regulates ribosomal biogenesis, protein translation, and cell growth/proliferation. In support of this finding, Nf1-/-fibroblasts and malignant peripheral nerve sheath tumors derived from NF1 patients exhibit Ras-dependent mTOR pathway hyperactivation (11) , indicating that mTOR is an important downstream effector of neurofibromin signaling. Second, Nf1-/-primary astrocytes exhibit a two-fold increase in cell motility that is associated with hyperactivation of the small GTPase Rac1 (9) . Similarly, Nf1-/-Schwann cells have enhanced chemokinetic and chemotactic migration compared to wild-type controls (12) . Third, Nf1-/-astrocytes demonstrate an eight-fold increase in protein synthesis rates associated with increased expression of ribosomal proteins, including the nuclear-cytoplasmic shuttling protein nucleophosmin (NPM; 10). Consistent with a role for neurofibromin in regulating protein synthesis and ribosomal biogenesis, the increased protein translation rate in Nf1-/-astrocytes is completely rescued by treatment with the mTOR inhibitor rapamycin.
In this study, we sought to define the molecular signaling events that underlie the increases in cell proliferation and cell motility characteristic of Nf1-/-astrocytes. In addition to regulating astrocyte proliferation, we find that mTOR regulates actin stress fiber formation and astrocyte motility, indicating that mTOR is an important regulator of actin cytoskeleton dynamics in astrocytes. We demonstrate that Rac1 functions downstream of mTOR to regulate actin stress fiber formation, astrocyte motility, and astrocyte proliferation. We identify nucleophosmin (NPM) as a critical target of mTOR signaling both in vitro and in vivo, and show that mTOR/Rac1 signaling is required for the increased expression of NPM in Nf1-/-astrocytes in vitro and in vivo. Moreover, we demonstrate that NPM regulates Nf1-/-astrocyte actin stress fiber formation as well as Nf1-/-astrocyte motility and proliferation in vitro. Together, these data identify a unique, mTOR-dependent signaling pathway that regulates actin cytoskeleton dynamics and cell proliferation in astrocytes and suggests that targeting these signaling intermediates may be useful for treating disorders characterized by mTOR pathway hyperactivation.
MATERIALS AND METHODS
Mice. Nf1 f/f mice were generously provided by Dr. Luis Parada (University of Texas Southwestern, Dallas, TX) and maintained as continuous breeding colonies by intercrossing (13) .
To conditionally inactivate Nf1 in astrocytes and to generate the Nf1 optic glioma model (Nf1 f/mut ;GFAP-Cre mice), Nf1 f/f mice were crossed with mice expressing Cre recombinase under the control of the human 2.2kb GFAP promoter as previously described (7, 8) . Mice were used in accordance with established animal studies protocols at the Washington University School of Medicine.
Primary astrocyte cultures. Murine neocortical astrocyte cultures were generated from postnatal day 2 Nf1 f/f pups as described previously (9) Eclipse TE300 inverted microscope, Japan) equipped with a digital camera (Optronics, Goleta, CA).
Western blotting. Astrocytes were serum-starved overnight, harvested by scraping in PBS, and lysed in NP40 lysis buffer (0.5% NP40, 150 mM NaCl, 50 mM Tris pH 7.6, 1 mM DTT) with protease inhibitors. Western blotting was performed as previously described (14) . All 
RESULTS
Increased cell proliferation and cell motility as well as decreased actin stress fiber formation in
Nf1-/-astrocytes are mediated by mTOR.
Previous studies in our laboratory have demonstrated that Nf1-/-astrocytes exhibit a twofold increase in cell proliferation that is restored to wild-type levels by treatment with the mTOR inhibitor rapamycin (Fig. 1A, 10 ). Under these conditions, there was no statistically significant effect of rapamycin treatment on wild-type astrocyte proliferation. In addition, Nf1-/-astrocytes exhibit a two-fold increase in cell motility and altered cell spreading, two processes that require proper organization of the actin cytoskeleton (8, 9, 15) . Recently, mTOR has also been shown to modulate actin cytoskeleton dynamics (16, 17) . Based on these observations, we sought to determine whether the increase in cell motility observed in Nf1-/-astrocytes was also mediated by mTOR. Using a Boyden chamber assay, the increase in Nf1-/-astrocyte motility was ameliorated by treatment with 10 nM rapamycin (Fig. 1B) . As before, no effect of rapamycin on wild-type astrocytes was seen. These data indicate that both increased astrocyte proliferation and motility are mediated by mTOR-dependent signaling in Nf1-/-astrocytes.
To extend our findings to other cytoskeleton properties, we next examined stress fiber formation in Nf1-/-astrocytes. Actin stress fibers are bundles of filamentous actin that extend through the cytoplasm and interact with membrane integrins at specialized regions of the cell membrane called focal adhesions to anchor the cell to the extracellular matrix (18) . Actin stress fibers have been used as a model system to study actin cytoskeleton dynamics. To directly visualize the actin cytoskeleton, we used fluorophore-labeled phalloidin, a fungal toxin that specifically binds actin. Whereas wild-type astrocytes exhibit numerous actin stress fibers, Nf1-/-astrocytes have few stress fibers (Fig. 1C) . In addition, we performed immunocytochemistry for vinculin, a protein localized to focal adhesions (19) . Consistent with a decrease in actin stress fibers, vinculin-positive, membrane-localized focal adhesions were nearly absent in Nf1-/-astrocytes whereas wild-type astrocytes had numerous focal adhesions ( Figure 1C ).
This stress fiber assay provided us with a tractable system to examine the effects of rapamycin on actin cytoskeleton dynamics as a function of time of treatment. In these studies, we treated wild-type and Nf1-/-astrocytes with a low concentration of rapamycin (10 nM) for various lengths of time (1 hour-24 hours). We observed a dramatic increase in actin stress fibers and vinculin-positive focal adhesions in Nf1-/-astrocytes even with 1 hour of rapamycin treatment (Fig. 1C) . In contrast, rapamycin had no effect on stress fiber formation or focal adhesions in wild-type astrocytes.
To confirm that the effect of rapamycin on actin stress fiber formation was mediated by mTOR, we introduced an mTOR-specific siRNA into wild-type and Nf1-/-astrocytes.
Knockdown of mTOR expression was confirmed by Western blot (Fig. 1D ). Similar to astrocytes treated with rapamycin, genetic inhibition of mTOR in Nf1-/-astrocytes restored actin stress fiber formation (Fig. 1D) . Together, these data indicate that mTOR regulates actin cytoskeleton dynamics and cell proliferation in Nf1-/-astrocytes.
mTOR-dependent regulation of actin stress fiber formation occurs independently of 4EBP1 and
S6K.
Because mTOR signaling underlies the hyperproliferation, increased cell motility, decreased actin stress fiber formation (Fig. 1) , and increased protein translation (10) in Nf1-/-astrocytes, we next sought to determine which mTOR downstream effectors are responsible for mediating these biological phenotypes. The best studied mTOR effectors are ribosomal S6 kinase (S6K) and elongation factor 4E binding protein 1 (4EBP1), proteins that regulate rates of protein translation. First, we examined the activation status of these effectors using phosphorylation-specific antibodies. While the target of S6 kinase, ribosomal S6, is robustly hyperactivated in Nf1-/-astrocytes, there was no change in 4EBP1 phosphorylation at Thr37/Thr46 ( Fig. 2A) , two sites required for 4EBP1 inactivation and translation initiation (20) .
These data suggest that 4EBP1 is not an important mediator of the mTOR-dependent abnormalities in cell proliferation and actin cytoskeleton dynamics in Nf1-/-astrocytes.
To directly examine the effect of S6K on actin stress fibers, we overexpressed human S6K in wild-type astrocytes. While S6K overexpression in wild-type astrocytes resulted in increased S6 activation (see Fig. 5A ), we observed no changes in actin stress fiber formation (Fig. 2B) . Similarly, rapamycin had no effect on actin cytoskeleton organization in S6K-expressing astrocytes. Taken together, these data suggest that rapamycin-sensitive, mTORdependent regulation of the astrocyte actin cytoskeleton occurs independently of the mTOR effectors 4EBP1 and S6K.
Rac1, but not PKCα is hyperactivated in Nf1-/-astrocytes.
Recently, protein kinase C α (PKCα) has been implicated in mTOR-dependent regulation of the actin cytoskeleton (17) . PKCα is regulated by phosphorylation Thr500, Thr641, and Ser660 and exhibits no activity without phosphorylation of all sites (21) . Using a commerciallyavailable antibody specific for PKCα phosphorylated at Thr641, we observed no changes in the PKCα phosphorylation in Nf1-/-astrocytes compared to wild-type astrocytes (Fig. 3A) .
Furthermore, PKCα activation was not sensitive to rapamycin treatment in astrocytes.
The small GTPase Rac1 has also been shown to act downstream of mTOR and modulate actin stress fiber formation (16) . Previous studies from our laboratory have shown that Nf1-/-astrocytes have increased levels of active, GTP-bound Rac1 (9) . To determine whether Rac1 hyperactivation was mediated by mTOR signaling in astrocytes, we treated wild-type and Nf1-/-astrocytes with rapamycin (10 nM) and assayed Rac1 activation. In these experiments, we found that rapamycin blocked Rac1 hyperactivation in Nf1-/-astrocytes ( Figure 3B ), indicating that Rac1 acts downstream of mTOR.
To determine whether Rac1 activation is required for the cytoskeleton abnormalities observed in Nf1-/-astrocytes, we inhibited Rac1 signaling using a mutant form of Rac1 (Rac1 N17 ) that functions in a dominant-negative fashion to inhibit the activity of endogenous Rac1. We found that the expression of Rac1 N17 in Nf1-/-, but not wild-type, astrocytes resulted in a dramatic increase in actin stress fiber formation (Fig. 3C) . Similarly, Rac1 N17 expression also restored the increased motility observed in Nf1-/-astrocytes to wild-type levels (Fig. 3C) . Taken together, these data indicate that increased Rac1 activity resulting from rapamycin-sensitive mTOR hyperactivation underlies the actin cytoskeleton abnormalities observed in Nf1-/-astrocytes.
Rac1 has also been shown to regulate cell proliferation in a variety of cell types (22, 23) and Rac1-/-mouse embryonic fibroblasts exhibit both impaired migration and cell proliferation (24) . To determine whether Rac1 regulates cell proliferation in Nf1-/-astrocytes, we expressed Rac1 N17 in wild-type and Nf1-/-astrocytes and examined BrdU incorporation. While expression of the dominant-negative Rac1 had little effect on wild-type astrocytes, it restored proliferation of Nf1-/-astrocytes to wild-type levels (Fig. 3D) . Taken together, these data indicate that Rac1
is an important regulator of mTOR-dependent actin stress fiber formation, cell motility, and proliferation in astrocytes.
Expression of nucleophosmin is regulated by mTOR in Nf1-/-astrocytes
Previous studies in our laboratory demonstrated that nucleophosmin (NPM) was one of several proteins that is highly expressed in Nf1-/-astrocytes (10). In addition, NPM is overexpressed in a variety of neoplasms, including prostate, ovarian and colon cancers.
Moreover, Npm-deficient fibroblasts exhibit decreased proliferation (25) . NPM is a nuclear export protein that interacts with nucleolar components of newly synthesized ribosomes to facilitate their transport from the nucleolus/nucleus to the cytoplasm and increase the rates of protein synthesis (26) . Expression of a NPM mutant that is unable to shuttle from the nucleus to the cytoplasm blocks ribosomal export (26) . In addition, treatment with rapamycin inhibits NPM protein expression in mouse embryonic fibroblasts (27) . In Nf1-/-astrocytes, we also found that mTOR inhibition by rapamycin dramatically reduced NPM expression in Nf1-/-astrocytes with no effect on wild-type astrocytes (Fig. 4A ).
To determine whether mTOR also regulates NPM expression in vivo, we employed a mouse model of NF1-associated optic glioma (Nf1
;GFAP-Cre;7). For these experiments, we treated 2 month old Nf1 f/mut ;GFAP-Cre with either rapamycin (5 mg/kg) or vehicle for 2 weeks (10 doses; n= 5 mice/group). We found that rapamycin treatment dramatically reduced mTOR pathway activation as evidenced by P-S6 immunohistochemistry (Fig. 4B) . Moreover, NPM expression was also decreased by rapamycin treatment. Together, these data demonstrate that mTOR is a critical regulator of NPM expression in astrocytes both in vitro and in vivo.
Because S6K/S6 and Rac1 were the mTOR effectors activated in Nf1-/-astrocytes, we next sought to determine whether either of these mTOR targets regulated NPM expression.
When S6K was overexpressed in wild-type astrocytes, there was no change in NPM expression, despite an increase in S6 phosphorylation (Fig. 5A ). This is in stark contrast to NPM regulation in primary MEFs where S6K is a potent inducer of NPM protein expression (27) and highlights the potential differences in mTOR signaling mechanisms between fibroblasts and astrocytes.
However, when Rac1 N17 was expressed in Nf1-/-astrocytes, NPM expression was attenuated. No change in S6 or Akt (data not shown) activity was observed following Rac1 N17 expression in Nf1-/-or wild-type astrocytes, again demonstrating that Rac1 functions downstream of mTOR.
Collectively, these results suggest that NPM functions downstream of mTOR and Rac1 via an S6K-independent mechanism (Fig. 5B) .
Nucleophosmin mediates alterations in actin cytoskeleton dynamics and cell proliferation in Nf1-
/-astrocytes.
To determine whether NPM regulates actin stress fiber formation in Nf1-/-astrocytes, we used two complementary approaches to disrupt NPM function. One of the major roles of NPM is to mobilize ribosomes from the nucleolus to the cytosol (26) . To disrupt this process, we expressed a mutant form of NPM (NPM double leucine mutant; NPMdL) that prevents NPM shuttling from the nucleolus to the cytoplasm. Previous studies from our laboratory have shown that this mutant behaves like a true dominant-negative protein, forming hetero-oligomers with endogenous NPM and blocking endogenous NPM from shuttling from the nucleus to the cytoplasm (26) . Expression of the NPMdL mutant rescued actin stress fiber formation in Nf1-/-astrocytes, but had no effect on wild-type astrocytes (Fig. 6A) . Second, we took advantage of the observation that NPM export from the nucleolus/nucleus is dependent on its interaction with the nuclear export protein CRM1 (26) . Leptomycin B is an antibiotic derived from Streptomyces that binds to CRM1 to specifically block CRM1-dependent nuclear export (28) . When Nf1-/-astrocytes were treated with 20ng/mL leptomycin B, actin stress fiber formation was rescued (Fig. 6A) . As before, no effect of leptomycin B treatment on wild-type astrocytes was observed.
Next, we directly assessed the effect of increased NPM expression on actin stress fiber formation in wild-type astrocytes. In these experiments, increased expression of His-tagged NPM resulted in decreased actin stress fiber formation in wild-type astrocytes which was rescued by leptomycin B treatment (Fig. 6B ), similar to Nf1-/-astrocytes. Together, these data demonstrate that increased expression of functionally mobile NPM protein mediates the decrease in actin stress fibers characteristic of Nf1-/-astrocytes.
To extend these observations, we next examined the effect of inhibiting NPM function on Nf1-/-astrocyte motility and proliferation. Similar to what we observed for rapamycin treatment and Rac1 N17 expression, expression of the NPMdL mutant restored cell motility (Fig. 6C ) and proliferation ( Fig. 6D ) to wild-type levels. Together, these data indicate that NPM is a critical mTOR effector important for regulating actin cytoskeleton dynamics and cell proliferation in Nf1-/-astrocytes.
DISCUSSION
mTOR has been shown to integrate signals from a variety of extracellular inputs, including growth factors, amino acids, glucose, ATP, and oxygen. In addition, mTORdependent signaling modulates numerous cellular properties, including cell proliferation, cell motility, and protein translation. We had previously found that Nf1-/-astrocytes exhibit defects in each of these properties, suggesting that Nf1-deficient astrocytes would represent a good model system to examine the mechanisms underlying mTOR regulation of cell proliferation and motility. In this study, we use both pharmacologic and genetic approaches to demonstrate that the Nf1 gene product neurofibromin regulates actin stress fiber formation, astrocyte motility, and astrocyte proliferation in an mTOR-dependent fashion. Using Nf1-/-astrocytes, we further show that neurofibromin regulation of these important biological properties are mediated by Rac1-dependent modulation of NPM expression and function.
The ability of mTOR to regulate these diverse biologic properties is not unique to neurofibromin. Studies on two other genetic disorders that predispose individuals to glioma formation have revealed roles for mTOR pathway regulation of cell proliferation and motility.
Inactivation of the tumor suppressor gene PTEN, a negative regulator of phoshotidylinositol-3-kinase (PI3K) signaling, causes Lhermitte-Duclos disease (29) and PTEN inactivation is the one of the most common genetic changes observed in human gliomas (30) . When Pten is inactivated in astrocytes, astrocyte proliferation is increased in vitro and in vivo (31) . Moreover, in a murine glioma model, Pten inactivation promotes astrocyte invasion in vitro and in vivo (32) . Similarly, tuberous sclerosis complex (TSC) is caused by mutations in one of two genes, TSC1 or TSC2, that negatively regulate mTOR signaling (33) . Inactivation of either Tsc1 or Tsc2 results in mTOR pathway hyperactivation in vitro and in vivo (34, 35) and inactivation of the Tsc1/2 complex promotes increased cell proliferation (36) (37) (38) . Moreover, loss of Tsc1 results in dramatic increases in NPM protein expression and NPM-dependent increases in ribosomal biogenesis (27) . The Tsc1/2 gene products also regulate actin cytoskeleton dynamics. Tsc1/2 inactivation results in a decrease in actin stress fibers (39) while TSC2 re-expression in TSC2-/-human cells promotes increased cell adhesion and decreased cell migration (40) . In addition, mTOR signals through two distinct protein complexes, one that is sensitive to rapamycin and one that is insensitive to rapamycin-mediated inhibition (16, 17) . Based on our observations that actin stress fiber formation in Nf1-/-astrocytes was rescued by short-term rapamycin treatment, we first examined mTOR signaling intermediates that are known to be sensitive to rapamycin, 4EBP1 and S6K. However, our data show that 4EBP1 activation is not altered by
Nf1 inactivation and overexpression of S6K does not alter actin stress fiber formation in astrocytes. These results suggest that neurofibromin regulation of mTOR signaling operates in a rapamycin-sensitive manner involving effectors other than S6K and 4EBP1. Consistent with our findings in astrocytes, S6K1/2 inactivation in mice impairs viability, but does not block cell proliferation (42) . Moreover, cell cycle progression in S6K1/2-/-mice remained sensitive to rapamycin. In addition, Pten inactivation in neurons results in an mTOR-dependent increase in neuronal soma size, which occurs independent of S6K1/2 signaling (43).
In Nf1-/-astrocytes, we found that another mTOR target, the small GTPase Rac1, acts downstream of mTOR to regulate actin stress fiber formation, cell motility, and cell proliferation.
We provide several lines of evidence that the small GTPase Rac1 One clue as to how mTOR/Rac1 hyperactivation might regulate astrocyte proliferation and motility derived from the observation that neurofibromin also regulates protein translation in a rapamycin-dependent mechanism (10) . Protein translation requires the synthesis of new ribosomes, a process that requires both rRNA transcription and processing as well as active shuttling of ribosomal proteins and RNAs from the nucleus to the cytoplasm. A key regulator of ribosome nuclear export is NPM, which functions as a nuclear-cytoplasmic shuttling protein.
Recent studies have shown that NPM directly interacts with ribosomal subunits to facilitate their nuclear export (26) . In this fashion, NPM promotes an increase in the cytoplasmic pool of actively translating ribosomes and increases protein synthesis rates. We show that NPM is overexpressed in Nf1-/-astrocytes in vitro and in a Nf1murine optic glioma model in vivo. This is consistent with previous studies demonstrating that NPM expression is induced by mitogenic signals (44, 45) . Furthermore, we demonstrate that NPM expression is regulated by mTOR, as mTOR inhibition by rapamycin inhibits NPM expression both in vitro and in vivo. This supports previous studies demonstrating that NPM is highly expressed in Tsc1-/-fibroblasts and is blocked by rapamycin treatment (27) . This increase in NPM expression is due to increased translation of existing NPM transcripts, as rapamycin treatment or Tsc1 re-expression suppresses NPM translation (27) .
Our data now show that the ability of NPM to shuttle between the nucleus and cytoplasm is a critical step in NPM-dependent regulation of actin cytoskeleton dynamics and proliferation, as inhibition of NPM shuttling using both genetic (NPMdL mutant) and pharmacologic (leptomycin B) inhibitors rescues these phenotypes in Nf1-/-astrocytes. The exact mechanism by which NPM regulates cell motility and proliferation in astrocytes is currently unclear. It is possible that NPM-mediated increases in cytosolic ribosomes could lead to the production of specific proteins involved in cell motility and proliferation. In this regard, NPM associates with mature ribosomes and actively translating polysomes in the cytosol (26) , suggesting that it has cytosolic functions at the polysome. At the polysome, NPM could regulate the translation of specific mRNA transcripts by the polysome machinery or assist in this process by supplying more cytosolic ribosomes available for translation. Support for this motion derives from a previous study which demonstrated that mitogenic signaling by Akt or Ras has distinct effects on the recruitment of specific mRNA transcripts to polysomes (46) . When Akt or Ras signaling was blocked by acute pharmacologic inhibition, there was little change in mRNA transcription but a dramatic change in the profiles of polysome-associated mRNAs. Future studies examining the profiles of actively translated proteins in wild-type and Nf1-/-astrocytes may elucidate the mechanism underlying NPM regulation of actin stress fiber formation, motility, and proliferation in astrocytes.
Together, these studies indicate that neurofibromin/mTOR signaling regulates actin cytoskeleton dynamics and cell proliferation in astrocytes and identifies Rac1 and NPM as components of the mTOR signaling pathway. This study suggests that therapies that specifically target these signaling molecules may prove useful for the treatment of NF1 and related disorders characterized by mTOR pathway activation. As gliomas frequently exhibit mTOR pathway activation (47) and NPM is highly expressed in human NF1-associated gliomas (D.H.G., unpublished observations), future studies aimed at understanding the molecular mechanisms that govern mTOR/Rac1/NPM regulation of astrocyte biology may lead to improved treatments for these deadly cancers. 
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